相似文献
1
Setting up an outcomes guarantee for pharmaceuticals: new approach to risk sharing in primary care.
BMJ. 2003 Mar 29;326(7391):707-9. doi: 10.1136/bmj.326.7391.707.
2
The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands.
Eur J Cardiovasc Prev Rehabil. 2009 Jun;16(3):371-6. doi: 10.1097/HJR.0b013e328329497a.
3
Denver group gives up FFS, successfully converts seniors to Medicare managed care.
Public Sect Contract Rep. 1999 Aug;5(8):120-2.
4
Where is the financial safety net for managed care physicians?
Am J Manag Care. 1998 Oct;4(10):1411-8.
5
Diabetes care in general practice: an approach to audit of process and outcome.
Br J Gen Pract. 1993 Jul;43(372):291-5.
6
Social deprivation and statin prescribing: a cross-sectional analysis using data from the new UK general practitioner 'Quality and Outcomes Framework'.
J Public Health (Oxf). 2007 Mar;29(1):40-7. doi: 10.1093/pubmed/fdl068. Epub 2006 Oct 27.
7
Data on specialty, PCP cap rates suggest wisdom of shared risk.
Capitation Rates Data. 1997;2:17-9.
8
Compensation monitor. Swim at your own risk.
Manag Care. 1998 Dec;7(12):17.
9
Medicines management. A tension seeker.
Health Serv J. 1999 Jul 22;109(5664):28-9.
10
Compensation monitor. Risk contracts help medical groups' bottom line.
Manag Care. 2008 Dec;17(12):11.
引用本文的文献
1
Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies.
Front Pharmacol. 2020 Dec 8;11:594446. doi: 10.3389/fphar.2020.594446. eCollection 2020.
2
Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends.
Pharmacoecon Open. 2018 Jun;2(2):109-123. doi: 10.1007/s41669-017-0044-1.
3
Drug approval status and recommendations for listing on public formularies: a Canadian cohort analysis.
BMJ Open. 2017 Oct 22;7(10):e018372. doi: 10.1136/bmjopen-2017-018372.
4
Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.
BMC Health Serv Res. 2010 Jun 7;10:153. doi: 10.1186/1472-6963-10-153.
5
Access with evidence development schemes: a framework for description and evaluation.
Pharmacoeconomics. 2010;28(2):143-52. doi: 10.2165/11530850-000000000-00000.
6
Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.
Pharmacoeconomics. 2010;28(2):113-42. doi: 10.2165/11530820-000000000-00000.
7
Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.
Pharmacoeconomics. 2010;28(2):93-102. doi: 10.2165/11314080-000000000-00000.
8
Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator.
BMJ. 2009 Dec 2;339:b4677. doi: 10.1136/bmj.b4677.
9
Rationing of drugs for rare diseases.
Pharmacoeconomics. 2006;24(4):315-6. doi: 10.2165/00019053-200624040-00001.
本文引用的文献
1
NHS to fund treatment for 10000 patients with MS.
BMJ. 2002 Feb 9;324(7333):316. doi: 10.1136/bmj.324.7333.316a.
2
Funding medicines for people with multiple sclerosis.
BMJ. 2001 Dec 15;323(7326):1379-80. doi: 10.1136/bmj.323.7326.1379.
3
Health department to fund interferon beta despite institute's ruling.
BMJ. 2001 Nov 10;323(7321):1087. doi: 10.1136/bmj.323.7321.1087.
Zotero 插件